UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
37.23
+0.25 (0.68%)
Oct 9, 2026, 2:14 PM EDT - Market open

UroGen Pharma Revenue

UroGen Pharma had revenue of $72.46M in the quarter ending June 30, 2026, with 199.22% growth. This brings the company's revenue in the last twelve months to $188.73M, up 100.27% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth. That makes UroGen Pharma the 17,846th largest company in the world by revenue and 2,916th in the United States.

Revenue (ttm)
$188.73M
Revenue Growth
+100.27%
P/S Ratio
9.58
Revenue / Employee
$629,113
Employees
300
Market Cap
1.82B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025109.79M19.39M21.45%
Dec 31, 202490.40M7.69M9.29%
Dec 31, 202382.71M18.36M28.52%
Dec 31, 202264.36M16.32M33.96%
Dec 31, 202148.04M36.24M307.17%
Dec 31, 202011.80M11.78M65,450.00%
Dec 31, 201918.00K-1.11M-98.40%
Dec 31, 20181.13M-7.03M-86.17%
Dec 31, 20178.16M-9.37M-53.46%
Dec 31, 201617.53M--
Dec 31, 2015---
Dec 31, 2014---
Dec 31, 2013---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Novavax413.80M
Maravai LifeSciences Holdings208.78M
Nuvation Bio169.90M
Mesoblast120.25M
Xencor104.97M
Intellia Therapeutics59.51M
Zymeworks37.13M
Generate Biomedicines26.48M
Revenue Rankings